Strategic Advisory: How Can Sponsors Leverage the FDA’s 2026 CMC Flexibility Framework for Cell and Gene Therapies?
Executive Summary: The Bottom Line On January 11, 2026, the FDA moved from negotiated flexibility to a standardized flexibility framework for Cell and Gene Therapies (CGT). For our clients, this…
